Introduction:TheEUROpeanBoneOver40SarcomaStudy(EURO-B.O.S.S.)wasthefirstprospectiveinternational studyforpatients41-65yearsoldwithhigh-gradebonesarcomatreatedwithanintensivechemotherapyregimenderivedfromprotocolsforyoungerpatientswithhigh-gradeskeletalosteosarcoma. Methods:Chemotherapybasedondoxorubicin,cisplatin,ifosfamide,andmethotrexatewassuggested,butpatientstreatedwithotherregimensattheinvestigators'choicewerealsoeligibleforthestudy. Results:Thepresentreportfocusesonthesubgroupof218patientswithprimaryhigh-gradeosteosarcoma.With amedianfollow-upof47months,the5-yearprobabilityofoverallsurvival(OS)was66%inpatientswithlocalized diseaseand22%incaseofsynchronousmetastases.The5-yearOSinpatientswithlocalizeddiseasewas29%in pelvictumors,and70%and73%forextremityorcraniofaciallocations,respectively. Inprimarychemotherapy,tumornecrosis≥90%wasreportedin21%ofthepatients.Therewerenotoxicdeaths; however,hematologicaltoxicitywasconsiderablewith32%ofpatientsexperiencing1ormoreepisodesofneutro-penicfever.Theincidenceofnephrotoxicityandneurotoxicity(mainlyperipheral)was28%and24%,respectively. Aftermethotrexate,23%ofpatientsexperienceddelayedexcretion,in4caseswithnephrotoxicity.
Introduction
Surgerycombinedwithadjuvantorneoadjuvantchemotherapyisconsideredstandardmanagementofpatientswith osteosarcoma (1) .Methotrexate(MTX),doxorubicin(Adriamycin[ADM]),cisplatin(CDP),andifosfamide(IFO)areconsideredthedrugswithprovenefficacyagainstosteosarcoma (1) andhavebeenusedaccordingtodifferentschedulesinchemotherapyprotocolsadoptedinlargestudies(2-7).Thepeak incidenceofosteosarcomaisintheseconddecadeoflife (1) and most of the studies with dose intensive chemotherapy includeonlypatientsuptotheageof40years (2, 3, 5, 6) .
Onlyafewstudyreportscontaindataontheuseofchemotherapy in patients older than 40 years with high-grade osteosarcoma (8) (9) (10) (11) (12) . The use of intensive chemotherapy regimensinthisagegroupmaybecomplicatedbyconcomitantdiseasesand/orphysiologicalchangesoccurringwithaging,includingdecreasedhematopoietictissueactivityaswell asdecreasedrenalfunctionwithitsimplicationsfordelayed drugexcretionandtoxicity (13) (14) (15) .
The rarity of primary high-grade osteosarcoma in adult and elderly patients requires collaborative efforts in order tocollectprospectivedata.Withthisbackground,theItalian Sarcoma Group (ISG), the Cooperative Osteosarcoma Study Group (COSS), and the Scandinavian Sarcoma Group (SSG) started an intergroup cooperative study (European over 40 Bone Sarcoma Study, EURO-B.O.S.S., ClinicalTrials.gov ID: NCT02986503) with the aim of evaluating the activity and toxicity of chemotherapy on bone sarcoma patients in this agegroup.Dataonsurvivalandchemotherapytoxicityinthe subgroupofpatientswithhigh-gradeosteosarcomaarepresentedhere.
Methods
EURO-B.O.S.S. was a prospective multicenter international study for 41-to 65-year old patients with high-grade bone sarcoma. The study enrolled patients with high-grade osteosarcoma,fibrosarcoma,malignantfibroushistiocytoma, leiomyosarcoma,dedifferentiatedchondrosarcoma,andangiosarcoma treated with antineoplastic agents used in chemotherapy protocols for younger patients with high-grade skeletalosteosarcoma.
Writteninformedconsentwassignedbythepatientsbeforestudyentry.ThestudywasapprovedbytheInstitutional ReviewBoardofeachparticipatinggroupand/orcenteraccordingtonationalandlocalrules.
WidesurgicalremovaloftheprimarytumorwiththeadditionofsystemictreatmentbasedonADM,CDP,IFO,MTXwas the mainstay of the proposed treatment strategy. Patients treatedwithotherregimensattheinvestigator'schoicewere alsoeligibleforthestudy.
Depending on the clinical features and the feasibility of adequatesurgicalremovalofthetumor,patientswerecandidatesforprimarychemotherapyfollowedbypostoperative chemotherapy,orpurelyadjuvantchemotherapy.
Pathological response to primary chemotherapy was determined according to the grading systems adopted by theparticipatinggroups:HuvossystemforSSG(16),SalzerKuntschiksystemforCOSS(17),andpercentageofnecrosis for ISG (18) . For patients with a histologic response graded HuvosI,Salzer-Kuntschik5-6orlessthan50%necrosis,MTX was to be added to the postoperative chemotherapy regimen,providedthatglomerularfunctionwasadequate.
An outline of the scheme of the suggested chemotherapy regimen is reported in Figure 1 . Details are available at http://www.italiansarcomagroup.org/wp-content/uploads/ 2014/04/EUROBOSS-testo-Version-2_1-05Sep2012.pdf.
Consideringtheobservationalcharacterofthestudy,patientswhomettheinclusioncriteriaandwhoweretoreceive other chemotherapy treatments according to institutional choicealsocouldbeenrolledinthestudy.
Surgical complete remission (SCR) was defined as completesurgicalremovalofallclinicallydetectablesitesofdisease(primarytumorandallmetastasesifmetastaticdisease waspresent).Patientswhodidnotobtaincompletesurgical remissionofallsiteswererecordedtohaveaneventonDay 1. Event-free survival (EFS) was calculated from the date of thediagnosticbiopsytothedateofthefirstofthefollowing adverseevents:death,distantorlocalrecurrence,secondary malignancyortreatment-relateddeath;orlastfollow-up.In SCRpatients,disease-freesurvival(DFS)wascalculatedfrom thedateofsurgerytothedateofdistantorlocalrecurrence or last follow-up. Overall survival (OS) was calculated from thedateofthediagnosticbiopsytothedateofdeathfrom anycauseorlastfollow-up.Survivalcurveswerecalculated by the Kaplan-Meier method and compared using the logranktestwiththeirrespective95%confidenceintervals(CI).
Chemotherapy toxicity was recorded according to National Cancer Institute expanded common toxicity criteria (version 2.0-March 1998) (19) . Toxicity and clinical-related eventassessmentincludedevaluationoftheincidenceofhematologic and nonhematologic toxicity (renal, hepatic, and neurotoxicity),theuseofgranulocytecolony-stimulatingfactors (G-CSFs), episodes of neutropenic fever, red blood cell (RBC), and platelet (PLT) transfusions. Chi-square evaluated byFisher'sexacttestwasusedforthecomparisonofcategorieswhenappropriate.Student'st-testorvarianceanalyses wereusedtocomparecontinuousvariables. (Fig.2) .
Results

WhenenrolmentwasclosedinDecember2014
TheywereincludedintheOSanalysis. ClinicalcharacteristicsarereportedinTableI.Inthe63pa-tientswithsynchronousmetastases,lunginvolvementwasdetectedin54(86%),combinedwithbonemetastasesin12,and in3withlymphnodeinvolvement.Eight(13%)oftheremainingpatientshadprimarybonemetastaseswithoutevidence of lung metastases, in 2 combined with lymph node or retroperitoneallesions.Arenalmetastasiswasreportedforthe remainingpatient.Among208evaluablepatients,157(76%) underwent tumor resection, 32 (15%) had an amputation, 1hadarotationplasty,1alaminectomy,17(8%)didnotundergosurgeryoftheprimarytumor.SCRwasmorefrequently obtainedinlocalizeddiseaseandextremitytumors(Tab.II).
Focusing on patients with localized disease, 110 of 151 (73%) received primary chemotherapy. Information on histologic response of the primary tumor was available for 106 (96%) patients. Overall 50 (47%) patients had less than 50% tumor necrosis and were therefore candidates for the postoperativeadditionofMTX.Chemotherapy-inducedtumor necrosisrangingfrom50%to89%wasreportedin34(32%) patients,and22(21%)patientshad≥90%tumor necrosis.
The vast majority of patients (183, 84%) were treated accordingtothesuggestedchemotherapyregimen(135pa-tients with nonmetastatic and 48 with metastatic disease). Theremaining35(16%)patients(20patientswithnonmet-astatic and 15 with metastatic disease) received different schemesthatincludedthesamedrugs-cisplatin,doxorubicin,andifosfamide-butadministeredassingleagentandnot incombination.
With a median follow-up of 35 months (range: 1-153months)forallpatientsand56months(1-153months) for 108 survivors, the 151 patients with localized disease had a 5-year OS of 66% (95% CI, 57-75) and those 57 with synchronous metastasesof23%(95% CI,6-39) (Fig. 3) .The median survival time of patients with metastatic disease was13months(4-141months).Therewerenodocumented treatment-relateddeaths.
Inpatientswithlocalizeddisease,aworseprobabilityof survivalwasobservedforthosewithhighbaselinevaluesof lactatedehydrogenase(LDH)andinpelviclocations(TabsIII andIV.
Inpatientswithlocalizeddisease,5-yearDFSwas52% (95% CI 43 to 61) and 5-year EFS was 50% (95% CI 42 to 59).Nosignificantdifferenceswerefoundaccordingtosex, age,site,histotype,baselinelevelsofserumalkalinephosphatase(SAP)andLDH.Forpatientswhoreceivedprimary chemotherapy, the 5-year DFS was 48% (95% CI, 37-58) and64%(95%CI,48-81)incaseofadjuvantchemotherapy (p=0.2). withlocalizeddisease(dataavailablefor93patients)5-year OSwas39%(95%CI,10-68)in15patientswhoreceived6or less cycles and 78% (95% CI, 64-85) in the 78 patients who received7ormorecycles(p=0.007).
Anoverallnumberof1,351cyclesreportedfrom178pa-tientswereevaluablefortoxicity.Overall,1ormoreepisodes ofG4whitebloodcellsorG3-4PLTtoxicitywerereportedfor For those patients who received chemotherapy accordingtothesuggestedscheme,the5-yearDFSwas50%(95% CI,40-59);whereasitwas63%(95%CI,40-87)intheother chemotherapy regimen (p = 0.9). The corresponding 5-year OS were 64.5% (95% CI, 55-74) and 85% (95% CI, 66-100), respectively(p=0.3).
Focusingonpatientswhoreceivedprimarychemotherapy,the5-yearDFSwas40%(95%CI,26-55)forlessthan50% tumor necrosis, 45% (95% CI, 27-63) with chemo-induced tumornecrosisrangingfrom50%to89%,and70%(95%CI, 49-90)with90%ormorenecrosis(p=0.1).Thecorresponding5-yearOSwere54%(95%CI,38-59),70%(95%CI,54-87) and78%(95%CI,59-97),respectively(p=0.2).Forpatients In 20% of patients, 1 or more episodes of neurotoxicity werereported.ThemajorityhadCDP-relatedperipheralneurotoxicityincludingG3in7.In1patient,aG4depressedlevel ofconsciousnesswasdocumentedfollowingIFO.
Regardingnephrotoxicity,48(26%)patientswerereportedtohaveexperiencedatleast1episode,mostlyG1orG2. OnepatienthadG3urinaryelectrolytewastingandG1creati-nineelevationgrade.TwopatientshadG3creatinineeleva-tion grade. Soon after chemotherapy completion based on ADM,CDP,andIFO,withoutMTX,1patientrequireddialysis forG4renaltoxicity.Priortoadministrationofthefinalchemotherapeutictreatment(IFO),herrenalfunctionhadbeen normal.
MTX-toxicitydatawereavailablefor48patientsforato-talof154MTXinfusions.Atleast1episodeofdelayedMTX excretion was reported for 11 (23%) of the 48 patients. In 4patients,delayedexcretionwasassociatedwithnephrotoxicity,whichwasrecordedasG3for1andasG1fortheother 3.In1patient,G1creatinineelevationgradewasreportedin spiteofnormalclearanceofthedrug.
Discussion
Themulti-institutional,internationalEURO-B.O.S.S.series described in this paper represents the largest prospectively collectedsourceofinformationonhigh-gradeosteosarcoma patientsabovetheageof40treatedfollowingauniformmul-timodal strategy of surgery and multi-drug chemotherapy. ThreeEuropeangroupsparticipatedinthestudy.Despitethe efforts made by the groups' secretariat, difficulties in data collectionwereencounteredandthisisalimitintheinterpretationoftheresults,whichispartiallyexplainedbytherarity ofthedisease,bythenumberoftheinvolvedcenters,andby theobservationalcharacteristicsofthestudy.
TheEURO-B.O.S.S.treatmentconceptledtoresultsthat seemcomparabletothosealsoachievedinyoungerpatients withprimaryhigh-gradeosteosarcoma,albeitatthecostof relevantsideeffects.
Mainly based on the documented efficacy observed in youngerpatients,thereisageneralagreementthatchemotherapyalsoshouldbeusedinpatientsolderthan40years withhigh-gradeosteosarcoma(1).Someretrospectivestudies including osteosarcoma patients over 40 treated with chemotherapyhavereportedsurvivalprobabilitiessimilarto those achieved in younger patients (8, 11) . A retrospective EMSOSstudy(10)observedanadvantageintermsofprognosis forthosepatientswho receivedchemotherapyabove those who did not; however, it did not provide details of the chemotherapy protocols used. In contrast, a recent paperposesdoubtsontheneedtoadministerchemotherapy tothesepatients (12) .Someretrospectivestudiesincluding osteosarcoma patients over 40 treated with chemotherapy havereporteddatashowingaprobabilityofsurvivalsimilar tothoseachievedinyoungerpatients (8, 11) .
Inourstudy,patientswithnonmetastatichigh-gradeosteosarcomaachieveda5-yearOSof66%,thosewithextremitytumorsa5-yearOSof70%,whichissimilartoreportsfrom studies in younger patients (2-7). Our study confirmed the poorprognosisofpatientswithpelvicosteosarcoma,asreportedinotherstudies (20,21) ;whereasthosepatientswith 63%and53%ofpatients,respectively.BloodorPLTtransfusionswerereportedfor52%and31%ofpatients,respectively. OneormorecyclesrequiredtheuseofG-CSFsin82%ofpa-tients and 1 or more episodes of febrile neutropenia were experiencedby32%. The database was not structured to collect data of cardiacfunctionasevaluatedwithechocardiograms.Nocasesof clinicallyrelevantcardiotoxicitywerereported. craniofacialosteosarcomahadaprobabilityofsurvivalsimilar tothatofpatientswithextremitytumors.
The prognosis of patients with primary metastatic diseasewaspoor,againasreportedforyoungerosteosarcoma patients (22) .Thecomparativelyhighpercentageofsynchronousmetastasesinpatientswithpelvicandcentralprimaries (mainlyspine),wheretumorsurgeryisparticularlychallenging,mightleadtoabiaswhencomparingseriesofolderand younger patients, as the relative frequency of axial tumors increaseswithage.Ofnote,comparedtocohortsofyounger patients,ourseriesshowedalowerpercentageofSCRforprimarymetastaticextremitytumors.Thus,wecannotexclude somereluctanceofsurgeonstoadoptanaggressivepolicyin thestudiedagegroup.
Inthepresentstudy,thechoiceofinitialtreatmentwas basedupontheclinicaljudgmentoftheinvolvedteams.Our data confirm the results of a previous randomized study, which demonstrated that both immediate surgery and postoperativechemotherapy,aswellascombinedpre-and postoperative chemotherapy, are acceptable management options (23) .
Inthepresentstudy,thepercentageofpatientswithagood (≥90%)histologicalresponsewaslowercomparedtothatreportedinyoungpatients(3,5),rangingfrom23%forextremity tumorstoonly12%inpelviclocations.Thismayberelatedto the suggested primary chemotherapy regimen. In our protocol,MTXwasnotusedpreoperativelyandthedosespercycle ofCDPandADMwerelowerthanthoseadoptedinyounger patients (3, 5) .Atthesametimewecannotexcludethatagerelatedpharmacokineticschanges(13-15)mayberesponsible forthereducedactivityofthedrugsinthissubsetofpatients. Nodirectconclusionsregardingtheroleofchemotherapy inthisagegroupofpatientscanbedrawn,butitisinteresting tonoticethelowerprobabilityofsurvivalobservedinthose patientswhoreceivedareducednumberofcyclesofchemotherapyduetorefusalortoxicity.
Chemotherapy-related toxicity was considerable, but no toxicdeathswererecorded.Hematologicaltoxicitywassimilar to that reported from younger cohorts of osteosarcoma patientstreatedwithmoreintensivechemotherapyregimens (3, 5, 6) .G-CSFswerecommonlyusedandaboutone-thirdof patientsexperiencedatleast1episodeoffebrileneutropenia.
The incidence of chemotherapy-induced peripheral neuropathy exceeded the frequency reported for younger patients treated with higher cumulative doses of CDP and ADM (3, 5, 6) . However, it is similar to reported levels in adultpatientswithotherCDP-treatedcancers,whoaremore prone to this side effect (24, 25) . Approximately one-third ofpatientsexperienced1ormoreepisodesofnephrotoxic-ity,mostlyG1,butin1casedialysiswasrequired.Theincidence of nephrotoxicity was higher than that reported for youngerpatients (3, 5, 6) ,probablyreflectinganage-related decreasedrenalfunctionnotdetectedbythelaboratorytests recommendedintheprotocol.
Although the methotrexate dose of 8 g/m² was lower thanthemorestandard12g/m²usedinyoungerpatients,its toxicitydataconfirmthatthedrugmustbeusedwithcaution inthisagegroup.However,whenclinicallyindicated,itseems feasibletoadministerMTXinapopulationofpatientsolder than40years.
In patients over 40 years of age suffering from primary high-grade osteosarcoma, we conclude that an aggressive approach with age-adapted chemotherapy and surgery can offer a probability of survival similar to that observed in younger patients. Either a combination of pre-and postoperative chemotherapy based upon the same drugs used for themoretypicalyoungerosteosarcomapatients,orpostoperative chemotherapy only (with the same total treatment duration)shouldbeconsideredstandardoptions.Chemotherapy-relatedtoxicitiesaresignificantandgenerallyhigherthan those reported from younger patient cohorts treated with moreintensiveregimens.
